Effects of rituximab and dexamethasone on regulatory and proinflammatory B-cell subsets in patients with primary immune thrombocytopenia

Keyphrases

• Primary Immune Thrombocytopenia 100%
• Rituximab 100%
• B Cell Subsets 100%
• B Cells 60%
• Interleukin-6 40%
• CD5+ B Cells 40%
• CD27 40%
• Treatment Regimen 20%
• Healthy Controls 20%
• Flow Cytometry 20%
• Newly Diagnosed 20%
• Interleukin-10 20%
• Adult Patients 20%
• Peripheral Blood Mononuclear Cells 20%
• Immune Thrombocytopenia 20%
• Healthy Donors 20%
• Cytokine Production 20%
• CD25 20%
• CD19 20%
• Inverse Correlation 20%
• Memory B Cells 20%
• Surface Markers 20%
• Platelet number 20%
• Intracellular Content 20%
• Breg 20%
• Cell Surface Markers 20%
• CD27+ B Cells 20%
• IL-10+ B Cells 20%

Immunology and Microbiology

• Dexamethasone 100%
• Idiopathic Thrombocytopenic Purpura 100%
• Rituximab 100%
• B Lymphocyte Subpopulation 100%
• B Cell 85%
• CD5 42%
• Interleukin-6 28%
• Regulatory B Cells 28%
• Cytokine 14%
• Surface Property 14%
• Peripheral Blood Mononuclear Cell 14%
• Cytokine Production 14%
• CD25 14%
• CD19 14%
• Platelet Count 14%
• Memory B Cell 14%
• Cell Surface Marker 14%

Neuroscience

• B Cell 100%
• Dexamethasone 100%
• Rituximab 100%
• B Lymphocyte Subpopulation 100%
• CD5 37%
• CD27 37%
• Peripheral Blood Mononuclear Cell 12%
• Cytokine Production 12%
• Platelet 12%
• Flow Cytometry 12%
• CD19 12%